The Centers for Medicare and Medicaid Services (CMS) has established a new Q-code for Yesafili (Biocon Biologics), an aflibercept biosimilar recently approved in the United States. The code, Q5155, “Injection, aflibercept-jbvf (yesafili), biosimilar, 1 mg,” will take effect on October 1, 2025.

Yesafili is a vascular endothelial growth factor (VEGF) inhibitor indicated for the treatment of neovascular (wet) age-related macular degeneration, macular edema following retinal vein occlusion, diabetic macular edema, and diabetic retinopathy.

Q-codes are temporary reimbursement codes established by CMS to facilitate billing and claims processing for specific products administered in a physician’s office or outpatient setting. The assignment of a Q-code allows payers and providers to track utilization of new therapies and enables more consistent reimbursement until a permanent J-code is designated. With the new billing code, providers will have a standardized pathway for submitting claims for Yesafili across government and commercial insurance plans. RP